Regulation of HSulf-1 expression by variant hepatic nuclear factor 1 in ovarian cancer

Cancer Research

Volumn 69, Issue 11, 2009, Pages 4843-4850

  Liu, Peng ^a   Khurana, Ashwani ^a   Rattan, Ramandeep ^a   He, Xiaoping ^a   Kalloger, Steve ^b   Dowdy, Sean ^a   Gilks, Blake ^b   Shridhar, Viji ^a,c  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CISPLATIN; HEPATOCYTE NUCLEAR FACTOR 1BETA; PACLITAXEL; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR II;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR XENOGRAFT;

ANIMALS; CARCINOMA; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE NUCLEAR FACTOR 1-BETA; HUMANS; MICE; MICE, NUDE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PROTEIN BINDING; RESPONSE ELEMENTS; RNA, SMALL INTERFERING; SULFOTRANSFERASES; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 66349097740     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3065     Document Type: Article

References (30)

1. Lai J, Chien J, Staub J, et al. Loss of HSulf-1 upregulates heparin-binding growth factor signaling in cancer. J Biol Chem 2003;278:23107-23117 (Pubitemid 36830377)
2. Narita K, Chien J, Mullany SA, et al. Loss of HSulf-1 expression enhances autocrine signaling mediated by amphiregulin in breast cancer. J Biol Chem 2007;282: 14413-14420 (Pubitemid 47100479)
3. Narita K, Staub J, Chien J, et al. HSulf-1 inhibits angiogenesis and tumorigenesis in vivo. Cancer Res 2006;66:6025-6032
4. Bach I, Mattei MG, Cereghini S, Yaniv M. Two members of an HNF1 homeoprotein family are expressed in human liver. Nucleic Acids Res 1991;19: 3553-3559 (Pubitemid 21912716)
5. Blumenfeld M, Maury M, Chouard T, Yaniv M, Condamine H. Hepatic nuclear factor 1 (HNF1) shows a wider distribution than products of its known target genes in developing mouse. Development 1991;113:589-599
6. Weng JP, Lehto M, Forsblom C, Huang X, Li H, Groop LC. Hepatocyte nuclear factor-1β (MODY5) gene mutations in Scandinavian families with early-onset diabetes or kidney disease or both. Diabetologia 2000;43: 131-132
7. Gagnon A, Ye B. Discovery and application of protein biomarkers for ovarian cancer. Curr Opin Obstet Gynecol 2008;20:9-13.
8. Tsuchiya A, Sakamoto M, Yasuda J, et al. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1β as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol 2003;163: 2503-2512 (Pubitemid 37466491)
9. Goff BA, Sainz de la Cuesta R, Muntz HG, et al. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 1996; 60:412-417 (Pubitemid 26077628)
10. Tammela J, Geisler J P, Eskew PN, Jr., Geisler HE. Clear cell carcinoma of the ovary: poor prognosis compared to serous carcinoma. Eur J Gynaecol Oncol 1998;19:438-440 (Pubitemid 28479390)
11. Behbakht K, Randall TC, Benjamin I, Morgan MA, KingS, Rubin SC. Clinical characteristics of clear cell carcinoma of the ovary. Gynecol Oncol 1998;70: 255-258 (Pubitemid 28430939)
12. Crotzer DR, Sun CC, Coleman RL, Wolf JK, Levenback CF, Gershenson DM. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol 2007;105:404-408 (Pubitemid 46590333)
13. Kato N, Toukairin M, Asanuma I, Motoyama T. Immunocytochemistry for hepatocyte nuclear factor-1β (HNF-1β): a marker for ovarian clear cell carcinoma. Diagn Cytopathol 2007;35:193-197
14. Köbel M, Kalloger SE, Carrick J, et al. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol 2009;33:14-21.
15. Kato N, Tamura G, Motoyama T. Hypomethylation of hepatocyte nuclear factor-1β (HNF-1β) CpG island in clear cell carcinoma of the ovary. Virchows Arch 2008; 452:175-180
16. Staub J, Chien J, Pan Y, et al. Epigenetic silencing of HSulf-1 in ovarian cancer: implications in chemoresistance. Oncogene 2007;26:4969-4978 (Pubitemid 47172647)
17. Chien J, Aletti G, Baldi A, et al. Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity. J Clin Invest 2006;116:1994-2004. (Pubitemid 44033323)
18. Chien J, Staub J, Avula R, et al. Epigenetic silencing of TCEAL7 (Bex4) in ovarian cancer. Oncogene 2005;24: 5089-5100 (Pubitemid 41129086)
19. Senkel S, Lucas B, Klein-Hitpass L, Ryffel GU. Identification of target genes of the transcription factor HNF1β and HNF1α in a human embryonic kidney cell line. Biochim Biophys Acta 2005;1731:179-190 (Pubitemid 41735113)
20. Lai JP, Chien J, Strome SE, et al. HSulf-1 modulates HGF-mediated tumor cell invasion and signaling in head and neck squamous carcinoma. Oncogene 2004;23: 1439-1447 (Pubitemid 38406839)
21. Lai J P, Chien JR, Moser DR, et al. hSulf1 sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparin-binding growth factor signaling. Gastroenterology 2004;126:231-248 (Pubitemid 38040739)
22. Kennedy AW, Biscotti CV, Hart WR, Webster KD. Ovarian clear cell adenocarcinoma. Gynecol Oncol 1989; 32:342-349 (Pubitemid 19074926)
23. Omura GA, Brady MF, Homesley HD, et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 1991;9:1138-1150
24. Yamada K, Tachibana T, Hashimoto H, et al. Establishment and characterization of cell lines derived from serous adenocarcinoma (JHOS-2) and clear cell adenocarcinoma (JHOC-5, JHOC-6) of human ovary. Hum Cell 1999;12:131-138
25. Kato N, Sasou S, Motoyama T. Expression of hepatocyte nuclear factor-1β (HNF-1β) in clear cell tumors and endometriosis of the ovary. Mod Pathol 2006;19:83-89
26. Tomassetti A, Mangiarotti F, Mazzi M, et al. The variant hepatocyte nuclear factor 1 activates the P1 promoter of the human α-folate receptor gene in ovarian carcinoma. Cancer Res 2003;63:696-704. (Pubitemid 36158150)
27. Terasawa K, Toyota M, Sagae S, et al. Epigenetic inactivation of TCF2 in ovarian cancer and various cancer cell lines. Br J Cancer 2006;94:914-921
28. Mendel DB, Khavari PA, Conley PB, et al. Characterization of a cofactor that regulates dimerization of a mammalian homeodomain protein. Science 1991;254: 1762-1767 (Pubitemid 21917519)
29. Mendel DB, Hansen LP, Graves MK, Conley PB, Crabtree GR. HNF-1α and HNF-1β (vHNF-1) share dimerization and homeo domains, but not activation domains, and form heterodimers in vitro. Genes Dev 1991;5:1042-1056
30. Baumhueter S, Courtois G, Crabtree GR. A variant nuclear protein in dedifferentiated hepatoma cells binds to the same functional sequences in the h fibrinogen gene promoter as HNF-1. EMBO J 1988;7:2485-2493